Hematology Revenue Cycle Overview
Hematology revenue cycle management is fundamentally different from most medical specialties because drug revenue (buy-and-bill) represents 50% to 70% of total practice revenue. In a typical hematology practice, the three revenue components are: drug reimbursement (50% to 70%), drug administration fees (15% to 25%), and cognitive E/M services (15% to 25%). The drug revenue component introduces unique financial risks (inventory carrying costs, drug price fluctuations, payer reimbursement changes) and unique opportunities (positive drug margins, multiple revenue streams per patient encounter) that do not exist in non-infusion specialties.
Drug Margin Analysis
Track drug margin by individual drug product monthly. Drug margin equals the payer reimbursement for the drug minus the acquisition cost. For Medicare, drug reimbursement is ASP + 6% (4.3% after sequestration). For commercial payers, drug reimbursement varies by contract but typically ranges from ASP + 10% to AWP minus 15%. A positive margin means the practice earns revenue on each drug administration beyond the administration fee. A negative margin means the practice loses money on each dose, which is unsustainable. Monitor ASP updates quarterly (CMS publishes new ASP rates every quarter) and compare them to your acquisition costs. If a drug margin turns negative, evaluate switching to a specialty pharmacy model for that drug.
Infusion Revenue Per Session
Calculate the total revenue per infusion session by combining drug reimbursement, administration fees, and any same-day E/M charges. The benchmark for hematology is $2,000 to $8,000 per infusion session for chemotherapy and $500 to $2,000 for non-chemotherapy infusions (iron, IVIG). If the average infusion session revenue falls below these ranges, investigate whether administration codes are being captured completely (are add-on codes for sequential infusions and extended hours being billed?), whether drug units are calculated correctly, and whether same-day E/M visits with modifier 25 are being billed when appropriate.
Administration Code Capture Rate
Track the average number of administration codes billed per infusion session. A multi-drug chemotherapy regimen should generate 3 to 5 administration codes per session (one initial code plus add-on codes for each drug and each time increment). If the average is below 2.5 codes per session for multi-drug regimens, review the infusion documentation for missing start/stop times and the coding process for missed add-on codes. Common missed codes include: hydration that ran independently for 31+ minutes (96360), additional hour codes (96415) when infusions run over 60 minutes, and sequential infusion codes (96417) for second and third chemotherapy drugs.
Days in Accounts Receivable
Hematology AR targets depend on the revenue type. Drug claims should have AR of 25 to 35 days because payers process drug claims with higher priority due to the high dollar values. Administration claims should match at 25 to 35 days since they are on the same claim as the drug. E/M claims should be at or below 28 days. If drug claim AR exceeds 40 days, investigate whether prior authorization numbers are being included on claims (missing auth triggers holds), whether J-code quantities are being disputed, and whether payer-specific drug reimbursement policies are being followed. High-dollar drug claims that age beyond 60 days represent significant cash flow risk.
Collection Rate and Drug Revenue Protection
Net collection rate for hematology should be 95% or higher for E/M and administration services and 97% or higher for drug reimbursement. The higher drug collection target reflects the fact that drug reimbursement rates are contractually defined (ASP-based or AWP-based) and should be predictable. If drug collection falls below 95%, investigate whether payers are applying unexpected discounts, denying waste (JW modifier claims), or reimbursing at a lower ASP rate than expected. Any drug with a collection rate below 90% requires immediate contract review with the payer to identify the reimbursement discrepancy.
Patient Financial Responsibility and Copay Assistance
Patient cost-sharing on hematology drugs can be substantial: 20% coinsurance on a $10,000 drug is $2,000 per treatment cycle. Most chemotherapy drugs have manufacturer copay assistance programs that reduce or eliminate the patient cost-sharing. Track copay assistance enrollment for every patient receiving high-cost drugs. For patients without copay assistance, discuss payment options before treatment begins because unplanned $2,000+ patient balances create collection challenges. Copay assistance programs typically cover $5,000 to $25,000 per year in patient cost-sharing, making treatment financially accessible and protecting the practice from patient bad debt.